Welcome to our dedicated page for Merit Medical Systems news (Ticker: $MMSI), a resource for investors and traders seeking the latest updates and insights on Merit Medical Systems stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Merit Medical Systems's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Merit Medical Systems's position in the market.
Rhea-AI Summary
Merit Medical Systems, Inc. (NASDAQ: MMSI) outlines the CEO succession planning process, with Fred Lampropoulos continuing as CEO and President through December 31, 2025. A special steering committee is developing a succession plan, with Korn Ferry assisting in identifying potential candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
-
Rhea-AI Summary
Merit Medical Systems, Inc. (MMSI) announced the pricing of $650.0 million aggregate principal amount of 3.00% Convertible Senior Notes due 2029 in a private placement to qualified institutional buyers. The offering was upsized from the previously announced offering of $550 million aggregate principal amount of notes. The notes will bear interest at 3.00% per year, payable semi-annually. The initial conversion rate of the notes will be 11.5171 shares of Merit’s common stock per $1,000 principal amount of notes, representing a premium of approximately 32.5% over the last reported sale price of Merit’s common stock on the Nasdaq Global Select Market on December 5, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.67%
Tags
-
Rhea-AI Summary
Merit Medical Systems, Inc. (Nasdaq: MMSI) plans to offer $550.0 million aggregate principal amount of Convertible Senior Notes due 2029 in a private placement. The notes will be senior unsecured obligations, with interest payable semiannually in arrears, and will be convertible to cash, shares of Merit's common stock, or a combination of both. The company intends to use the net proceeds for general corporate purposes, including repayment of existing debt, sales and marketing activities, research and development, and potential acquisitions. Merit also plans to enter into capped call transactions to reduce potential dilution to its common stock upon conversion of notes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.37%
Tags
Rhea-AI Summary
Merit Medical Systems reports Q3 2023 revenue of $315.2 million, up 9.8% YoY. Raises fiscal year 2023 financial guidance. GAAP operating margin increases to 11.1% in Q3 2023. Non-GAAP operating margin increases to 18.3% in Q3 2023. GAAP EPS increases to $0.44 in Q3 2023. Non-GAAP EPS increases to $0.75 in Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.68%
Tags
-
Rhea-AI Summary
Merit Medical Systems expands Maestro Microcatheter product line with new longer length for radial embolization procedures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
-
Rhea-AI Summary
Merit Medical Systems, Inc. to release Q3 2023 financial results on October 26, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
Rhea-AI Summary
Merit Medical Systems, Inc. announces the U.S. commercial release of its Aspira Bottle, expanding its drainage portfolio. The bottle offers a compassionate at-home treatment option for patients with pleural effusions and malignant ascites. The advanced design requires 23% less storage space and allows users to control drainage speed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
-
News
Rhea-AI Summary
Merit Medical Systems, Inc. (NASDAQ: MMSI) announced the completion of enrollment in its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal study, comparing the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) to percutaneous transluminal angioplasty for the treatment of stenosis/occlusion in the venous outflow circuit in patients undergoing hemodialysis. The study enrolled 244 patients with AVFs and 113 patients with AVGs across multiple countries. Merit intends to file primary outcomes with the FDA for Premarket Approval after six months post-enrollment completion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.97%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.08%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
Merit Medical Systems Inc
Nasdaq:MMSI
MMSI Rankings
MMSI Stock Data
4.59B
56.54M
2.44%
101.72%
3.41%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
SOUTH JORDAN
About MMSI
merit medical systems, inc. (nasdaq: mmsi) is a leading manufacturer of medical devices used in diagnostic & interventional cardiology & radiology procedures. its primary products consist of inflation devices used in angioplasty, stent placement & discography; diagnostic & therapeutic catheters used for various procedures in cardiology & radiology; guide wires used to place balloon angioplasty catheters within a patient's coronary arteries; products used to manage & monitor the administration of contrast & other fluid solutions during diagnostic & therapeutic procedures; thrombolytic catheters & fluid dispensing systems; angiography accessories; & standard & custom angiography kits. headquartered in south jordan, utah, a suburb of salt lake city, merit employs approximately 1,900 people worldwide. merit markets its products in the united states & europe (direct sales force) & the world (distributors). they call directly on physicians & clinicians in hospitals & clinics worldwide. the c